Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 358

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 358
---
.5, 1 mg/kg) and compared to those of vehicle and of donepezil (2 mg/kg). Long -termepisodic memory was tested in the NOR test, using a 3 -daysinterval between the acquisition session (called sample trial) and the retention session (called choice trial). The results of the study showed NLS -11improved the recognition of the familiar object, i.e. improved memory and suggest that NLS -11induced a long -termmemory improvement which was significant and of the same extent to that induced by donepezil. At doses tested, NLS -11did not reduce exploratory behavior, contrary to donepezil, suggesting that NLS -11may induce less side effect than donepezil. NLS-12 NLS -12(Oxafuramine) is a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist, improved long -termepisodic memory in mice. Donepezil was used as positive control drug. A preclinical study was conducted to observe the effects of NLS -12on the memory in the novel object recognition test in mice. The dose -rangingstudy using C57BL/6 male mice: 8 groups (N = 16 mice/group) were subjected to the effect of NLS -12(1,4, 8 mg/kg) and compared to those of vehicle and of donepezil (2 mg/kg). Long -termepisodic memory was tested in the NOR test, using a 3 -daysinterval between the acquisition session (called sample trial) and the retention session (called choice trial). NLS -12dose -dependentlyimproved the recognition of the familiar object, i.e. improved memory. This effect was significant at 8 mg/kg and was not significantly different to that of donepezil. The recognition of the familiar object was not modified by NLS -12(1 mg/kg) and was improved in a non -significantmanner by NLS -12(4 mg/kg). The results of this pre -clinicalstudy suggest that NLS -12induced a long -termmemory improvement which was significant and of the same extent to that induced by donepezil. Aexon CNS Platform Aexon conducts research on new compounds to address unmet needs in neurodegenerative disorders, defined by the breakdown of neurons over time. Alzheimer’s, Parkinson’s, Huntington’s, Narcolepsy and Amyot